Printer Friendly

RNAi licenses database platform from GeneGo.

GeneGo, Inc. (St. Joseph, MI), a leading provider of software and databases for systems biology, said that RCL has licensed MetaCore for its RNA interference drug discovery efforts. MetaCore is an integrated platform for the analysis of different types of experimental data in drug discovery. MetaCore applies a proprietary, manually curated, human protein interaction and pathway database to drug discovery. The flexible database architecture enables straightforward integration of in house and third party software and databases. MetaCore also has easy to use software for building, visualization and analysis of tissue specific biological networks with and without experimental data.

"We looked at several systems biology packages and found that MetaCore suited our needs the best," said Mr.Yukikazu Natori, Chairman of RNAi. "The system is flexible for customization, and the GeneGo team is open minded for collaborative development. We needed a flexible partner that was willing to integrate with our current siRNA technology."

"We welcome RCL as our first Japanese customer," said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "RCL has built an impressive and unique technology portfolio in the RNA interference area. Their findings are very synergistic with pathway analysis of complex diseases we are working on. We consider this agreement as the first step in long term collaboration in the intersection of these two exciting technologies."

GeneGo is developing systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo's flagship product, MetaCore, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug is designed for prediction of human metabolism and toxicity for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.

RCL is a biotechnology company in the field of functional genomics based on RNA interference. RCL conducts two types of business. One is research support business for life science and the other is drug discovery business. RCL's unparallel RNA interference science and technology achieves high specificity of gene knock-down while minimizing unwanted off-target effects. RCL has already identified and applied the patent about 820,000 kinds of siRNA/shRNA/Oligo interference for all of human and mice genes known publicly. RCL's licensees can access to the most comprehensive RNAi design system, siDirect with usage of 820,000 sequences and get high-quality chemically synthetic siRNA manufactured by Proligo, siPerfect at the most attractive price in the market. RCL currently has two business offices and a wet lab and a dry lab in Japan with 20 employees and plans to enhance GMP functionality for preclinical study this year.

GeneGo, Inc.


COPYRIGHT 2005 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RCL; GeneGo, Inc
Comment:RNAi licenses database platform from GeneGo.(RCL)(GeneGo, Inc)
Publication:BIOTECH Patent News
Geographic Code:1U3MI
Date:Jan 1, 2005
Previous Article:Quest granted exclusive license from University of Texas to use blood protein technology.
Next Article:Mergen settles patent litigation with OxfordGene.

Related Articles
Alnylam licenses gene silencing technology from Cold Spring Harbor.
Alnylam and Cenix enter into RNAi research service agreement.
Benitec grants ddRNAi license to Artemis for development of transgenics.
Sirna Therapeutics granted two key patents on its RNA interference technology.
Alnylam grants Nastech a License to develop RNAi therapeutics against TNF-alpha.
Sigma-Aldrich licenses fundamental RNAi patent estate from Alnylam.
Intradigm Strengthens RNA Interference (RNAi) Position with MIT License.
Intradigm Announces Allowance of Key RNA Interference Patent Patent Covers Small Interfering RNA Structural Features Tied to Increased Efficacy and...
Silence Receives Allowance for its Core RNAi Patent.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters